Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide as an Adjunct to Nicotine Patch for Smoking Cessation and Weight Gain Prevention
NCT05610800Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in nicotine dependence comparing Exenatide, NRT, and Smoking Cessation Counseling with Placebo, NRT, and Smoking Cessation Counseling (2 arms). Primary endpoints: 4-week continuous abstinence at 15 weeks and Weight change at 15 weeks. Started Dec 2022; status: completed.
02
Drugs
exenatide
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT05610800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610800.